Ecron Acunova Announces Key Leadership Change – Marty Boom appointed as Managing Director
Ecron Acunova, a subsidiary of TAKE Solutions and specialized provider of clinical services to Pharma & Biotech companies, announced the appointment of Marty Boom as Managing Director.
Mr. Boom takes over this position from his former role as Head of Operations of TAKE Solutions’ Life Sciences brand Navitas, where he made significant contributions to the growth of the organization with his leadership spanning both the US and India geographies. Mr. Boom has rich experience in managing diverse global teams and has led global business improvement assignments for companies like Bayer HealthCare, Pfizer, Johnson & Johnson, Roche, and many others in most areas of Pharmaceutical Drug Development and Supply Chain. Mr. Boom will be based at the Headquarters in Frankfurt, Germany.
About Ecron Acunova
Ecron Acunova (www.ecronacunova.com ) is a full service CRO with predominant presence in Europe and Asia with 30 years of track record. EA offers full-service clinical research including clinical operations, data management, biostatistics, pharmacovigilance, PK/PD services and central lab to pharma, biotech, medical device, nutrition and diagnostic companies.
Ecron Acunova is a wholly owned subsidiary of TAKE Solutions Ltd .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
TX-ASURAGEN17.1.2018 09:02 | pressemeddelelse
Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer
MA-LOGIN-VSI17.1.2018 09:02 | pressemeddelelse
Login VSI Announces Free Meltdown/Spectre Emergency Edition
NTT-COMMUNICATIONS17.1.2018 07:02 | pressemeddelelse
NTT Com Granted Microsoft's Gold Cloud Platform Status Globally
CA-INCELLDX,-INC.17.1.2018 06:03 | pressemeddelelse
Premas, IncellDx Ink India Distribution Agreement
IPSEN16.1.2018 23:08 | pressemeddelelse
Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma
NY-IFF16.1.2018 22:18 | pressemeddelelse
IFF to Release Fourth Quarter & Full Year 2017 Results February 14
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum